JDRF is pleased to report important progress in the development of an artificial pancreas, a device that would ease the burden of living with type 1 diabetes.
Clinical Trial Success
A JDRF clinical trial in America using the Hypoglycaemia-Hyperglycaemia Minimiser (HHM) System (developed by Animas Corporation in a partnership with JDRF) was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely.
The trial involved 13 participants with type 1 diabetes, who used the HHM system for approximately 24 hours. An algorithm was developed to predict whether blood sugar levels would rise or fall with pre-set thresholds to deliver or suspend insulin delivery, with a safety module run from a laptop. Insulin and food variables were manipulated in the study to challenge and assess the system. The trial showed that the HHM system worked as expected. Rising and falling blood glucose levels were automatically tracked, and insulin doses increased or reduced as necessary.
The HHM system includes an insulin pump, a CGM, and special software used to predict changes in blood glucose. The system represents a key stage in the development of a first-generation closed-loop artificial pancreas system for people with type 1 diabetes.
Dr Dorota Pawlak, Head of Research Development at JDRF says “An artificial pancreas system that can not only detect, but can predict high and low blood sugar levels and make automatic adjustments to insulin delivery would be a major advance for people with Type 1 diabetes. Such a system could alleviate the huge burden of managing this disease”.
Further clinical trials will allow refinement of the mechanics and software that will ultimately lead to a commercial artificial pancreas.
Trial findings were presented at the 72nd Annual ADA Conference in June. See the JDRF press release here.
JDRF Collaboration on Glucose Monitors
JDRF International has announced a new collaboration with the Helmsley Charitable Trust and BD Medical. This collaboration is part of the JDRF-HCT Sensor Initiative for accelerating development of glucose monitors.
This collaboration aims to accelerate the development of BD Medical’s glucose sensoring technology. By supporting the progress of this technology, JDRF hopes it can be used as a step in the development of fully automated artificial pancreases.
Continuous glucose monitoring (CGM) is an integral component of the future artificial pancreas. CGM can significantly improve control and management of type 1 diabetes, and decrease the frequency of fluctuations in extreme blood glucose levels.
Mike Wilson, CEO of JDRF Australia says “JDRF is committed to developing technologies that will make it easier for people to manage their type 1 diabetes. Accurate CGM technology is essential to the development of the artificial pancreas, which could change the lives of people with type 1”.